ALTX 1095
Alternative Names: ALTX-1095Latest Information Update: 28 Aug 2023
At a glance
- Originator Alchemab
- Class Antibodies
- Mechanism of Action HD protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Huntington's disease
Most Recent Events
- 18 Jul 2023 ALTX 1095 is available for licensing as of 18 Jul 2023. https://www.alchemab.com/our-science/samples/
- 18 Jul 2023 Preclinical trials in Huntington's disease in United Kingdom (Parenteral) (Alchemab pipeline, July 2023)
- 26 Apr 2023 Pharmacokinetics and pharmacodynamics data from a preclinical study in Huntington’s disease released by Alchemab